Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew White

Allergy & Immunology San Diego, CA Medical Doctor

NPI 1750352761 CMS profile 79540

3811 Valley Centre Dr, San Diego, CA 92130

Open in the dashboard

General payments

$752,284

1,519 records reported · program years 2019–2025

Research payments

$5,373

Paid to them · 7 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$463,512 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Andrew White of San Diego, CA is reported in the CMS Open Payments database as having received $752,284 across 1,519 general payments and $5,373 in research payments paid to them. Separately, studies naming them as principal investigator received $463,512 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $147,061 278
2025 Research $4,414 5
2024 General $145,660 277
2023 General $189,933 293
2022 General $120,511 252
2021 General $51,214 165
2020 General $35,579 83
2020 Research $959 2
2019 General $62,326 171

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew White
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Andrew White were reported at $147,061. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Andrew White Allergy & Immunology median Middle half National median
2019 $62,326 $594 $163–$1,512 $163
2020 $35,579 $426 $106–$1,233 $114
2021 $51,214 $638 $157–$1,708 $132
2022 $120,511 $790 $205–$1,961 $149
2023 $189,933 $852 $220–$2,147 $160
2024 $145,660 $865 $203–$2,267 $164
2025 $147,061 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $205,573 268 payments
  2. Regeneron Healthcare Solutions, Inc. $125,074 194 payments
  3. AstraZeneca Pharmaceuticals LP $116,430 205 payments
  4. Blueprint Medicines Corporation $111,847 112 payments
  5. Genzyme Corporation $78,573 111 payments
  6. OptiNose US, Inc. $53,427 86 payments
  7. Genentech USA, Inc. $13,852 71 payments
  8. Sanofi US Services Inc. $13,028 8 payments
  9. ALK-Abello, Inc $11,927 28 payments
  10. Regeneron Pharmaceuticals, Inc. $8,973 8 payments
  11. Other $13,580 428 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $449,870 199 payments
  2. Honoraria $104,805 38 payments
  3. Consulting Fee $95,003 58 payments
  4. Travel and Lodging $67,692 158 payments
  5. Food and Beverage $34,644 1,059 payments
  6. Education $272 7 payments
Products named General payments · program years 2019–2025
  1. NUCALA $187,684 185 payments
  2. AYVAKIT Oncology / Rare Diseases $92,316 92 payments
  3. DUPIXENT Inflammation And Immunology $87,233 155 payments
  4. DUPIXENT Immunology $63,485 98 payments
  5. Xhance $53,427 86 payments
  6. TEZSPIRE $43,723 65 payments
  7. FASENRA Respiratory $34,933 65 payments
  8. DUPIXENT Immunology And Inflammation $27,212 31 payments
  9. FASENRA Respiratory $27,179 31 payments
  10. AYVAKIT Gastroenterology $17,367 10 payments
  11. Other $81,830 767 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $4,414 5 payments
  2. Sanofi-Aventis U.S. LLC $959 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

1,357

Median for Allergy/ Immunology: 449

Drug cost

$1,300,643

Median for Allergy/ Immunology: $169,700

Branded share of claims

47.9%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 108 $414,626
Xolair Omalizumab Brand 92 $345,050
Nucala Mepolizumab Brand 46 $175,497
Dupixent Syringe Dupilumab Brand 38 $144,459
Gammaplex Immun Glob G(Igg)/Gly/Iga 0-50 Brand 21 $40,735
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 39 $34,031
Cromolyn Sodium Generic 56 $29,322
Spiriva Respimat Tiotropium Bromide Brand 34 $26,569
Xhance Fluticasone Propionate Brand 18 $13,697
Breo Ellipta Fluticasone/Vilanterol Brand 28 $12,101

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$619,290

Of which drugs: $532,625

Medicare patients

488

Average age 73

Services billed

32,554

320 women, 168 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 55%
Arthritis 50%
Osteoporosis 30%
Depression 21%
COPD 20%
Ischemic heart disease 19%
Diabetes 15%
Chronic kidney disease 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, omalizumab, 5 mg J2357 Office 54 9,090 $195,780
Injection, mepolizumab, 1 mg J2182 Office 21 8,700 $180,682
Injection, tezepelumab-ekko, 1 mg J2356 Office 14 7,980 $95,489

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$32,250 146 —
NUCALA
$24,675 46 8,700
AYVAKIT
$22,684 — —
TEZSPIRE
$15,958 — 7,980
Xhance
$15,069 18 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

1,526 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record